$49.83
0.24% today
Nasdaq, Dec 02, 06:14 pm CET
ISIN
US80105N1054
Symbol
SNY

Sanofi Sponsored ADR Stock price

$49.95
-0.10 0.20% 1M
+0.76 1.55% 6M
+1.72 3.57% YTD
+1.99 4.15% 1Y
+4.08 8.89% 3Y
-0.98 1.92% 5Y
+5.90 13.39% 10Y
+9.12 22.32% 20Y
Nasdaq, Closing price Mon, Dec 01 2025
+0.07 0.14%
ISIN
US80105N1054
Symbol
SNY
Industry

Key metrics

Basic
Market capitalization
$121.4b
Enterprise Value
$136.3b
Net debt
$14.9b
Cash
$10.3b
Shares outstanding
1.2b
Valuation (TTM | estimate)
P/E
3.8 | 5.4
P/S
1.6 | 2.3
EV/Sales
1.8 | 2.6
EV/FCF
-
P/B
1.4
Dividends
DPS
$2.20
Yield 1Y | 5Y
4.4% | 4.0%
Growth 1Y | 5Y
7.8% | 5.3%
Payout 1Y | 3Y
39.7% | 32.9%
Increased
2 Years
Financials (TTM | estimate)
Revenue
$77.7b | $52.6b
EBITDA
$21.0b | $16.3b
EBIT
$18.3b | $13.2b
Net Income
$16.0b | $11.2b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
19.9% | 2.4%
EBITDA
21.2% | 33.1%
EBIT
25.6% | 31.0%
Net Income
99.6% | 73.3%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
72.3%
EBITDA
27.1% | 31.0%
EBIT
23.6%
Net
20.6% | 21.3%
Free Cash Flow
-
Financial Health
Equity Ratio
58.4%
Return on Equity
7.2%
ROCE
16.2%
ROIC
13.0%
Debt/Equity
0.3
More
EPS
$13.1
FCF per Share
-
Short interest
0.3%
Employees
83k
Rev per Employee
$620.0k
Show more

Is Sanofi Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Sanofi Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a Sanofi Sponsored ADR forecast:

23x Buy
79%
5x Hold
17%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a Sanofi Sponsored ADR forecast:

Buy
79%
Hold
17%
Sell
3%

Financial data from Sanofi Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
77,680 77,680
20% 20%
100%
- Direct Costs 21,524 21,524
10% 10%
28%
56,157 56,157
24% 24%
72%
- Selling and Administrative Expenses 15,026 15,026
13% 13%
19%
- Research and Development Expense 13,155 13,155
34% 34%
17%
21,041 21,041
21% 21%
27%
- Depreciation and Amortization 2,699 2,699
2% 2%
3%
EBIT (Operating Income) EBIT 18,341 18,341
26% 26%
24%
Net Profit 16,022 16,022
100% 100%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Sanofi Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanofi Sponsored ADR Stock News

Negative
Investors Business Daily
6 days ago
Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud investigation.
Neutral
GlobeNewsWire
7 days ago
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Negative
Reuters
12 days ago
Texas Attorney General Ken Paxton sued Bristol Myers Squibb and Sanofi , accusing the drugmakers of failing to disclose that Plavix, which is used to prevent blood clots, does not work effectively for many patients.
More Sanofi Sponsored ADR News

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Head office France
CEO Paul Hudson
Employees 82,878
Founded 1994
Website www.sanofi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today